We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Bilal
Tahir
b.tahir@sheffield.ac.uk
Prof
matthew
hatton
matthewhatton@nhs.net
Malignant neoplasms of respiratory and intrathoracic organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Lung cancer is the most common cancer in Yorkshire with over 4,500 new cases diagnosed each year and survival rates remain very disappointing with less than 10% of patients still alive 5 years after their diagnosis. Radiotherapy and surgery are the cornerstones of potentially curative treatment but both run the risk of serious complications, especially in patients with poor lung function. Sadly, the most lung cancer patients in Yorkshire have other lung diseases reducing their lung function increasing the risk of radiotherapy or surgery.
Selecting the best treatment for individual patients, surgery or radiotherapy, is a complex process requiring comprehensive and accurate assessment of lung function. Currently, these decisions are made using relatively simple lung function tests that only provide whole-lung measures which often poorly predict lung function following treatment.
More accurate lung function tests would help doctors and this study investigates if a cutting-edge functional lung MRI scan, developed and used in Sheffield, can give extra information that can help identify the patients most likely to benefit from radiotherapy and surgery and enable doctors to offer these treatments to a wider range of patients.
This study assesses the feasibility of introducing functional lung MRI into the current lung cancer diagnostic pathways across a cancer network and will look at its potential impact on decision making.
40 patients from South Yorkshire (Sheffield and Doncaster) being considered for curative surgery or radiotherapy will be recruited to this study. Patients will undergo lung function tests and imaging at 3 timepoints: prior to treatment, 3 and 12 months post-treatment.
This study has the potential to directly benefit lung cancer patients improving selection for treatment and contribute to our understanding of lung function when selecting patients for potentially curative treatment options.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Imaging;
You can take part if:
You may not be able to take part if:
• Any contraindication(s) to MRI scanning as per the MRI Screening Form and standard (clinical) operating procedure used by the Unit of Academic Radiology, Sheffield. • Unable to tolerate MRI scanning • Significant co-morbidities that exclude radical treatment • Patients who are pregnant • Patients unable to give informed consent • Patients with stage 4 or 5 chronic kidney disease, defined by creatinine clearance less than 30ml/min as estimated by the Cockcroft-Gault equation (due to gadolinium contrast use). • Patients with previous allergy to gadolinium contrast.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST and funded by YORKSHIRE CANCER RESEARCH .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 45026
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
